<DOC>
	<DOC>NCT00601861</DOC>
	<brief_summary>The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma</brief_summary>
	<brief_title>Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer</brief_title>
	<detailed_description>The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The trial was terminated as a result of a strategic decision by the sponsoring company.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Stage III melanoma ECOG performance status 01 Signs of stage IV melanoma Safety variables</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>